Background Omalizumab is the only biological agent approved for patients with chronic
spontaneous urticaria (CSU), but no biomarker is well established for predicting clinical …

In chronic spontaneous urticaria (CSU), wheals, angioedema, or both appear spontaneously
for> 6 weeks. Current recommended treatment options for urticaria target mast cell …

Gender differences are increasingly emerging in every area of medicine including drug
therapy; however, specific gender-targeted studies are infrequent. Sex is a fundamental …

Background Omalizumab (OMA) dramatically improves disease control and quality of life in
patients with chronic urticaria (CU). Objective We aimed to evaluate the discontinuation …

Introduction: The possible influence of sensitization to aeroallergens on omalizumab
response in chronic spontaneous urticaria (CSU) has been insufficiently investigated. This …

Хроническая крапивница (ХК)–заболевание кожи, которое характеризуется
ежедневными или частыми появлениями волдырей, зуда и/или ангиоотеков (АО) …